← Back to guidelines
Emergency Medicine3 papers

Unverricht-Lundborg syndrome

Last edited: 4/10/2026

Overview

Unverricht-Lundborg syndrome (EPM1) is a rare, autosomal recessive progressive myoclonic epilepsy characterized by stimulus-induced myoclonus and generalized tonic-clonic seizures 1. It is the most common form of progressive myoclonic epilepsy in Finland 1.

Diagnosis

  • Diagnosis is based on clinical presentation of stimulus-induced myoclonus and generalized tonic-clonic seizures 1.
  • Genetic testing for mutations in the PIGL* gene is diagnostic 1.

    Management

  • Treatment aims to control seizures and myoclonus 1.
  • First-line treatment includes levetiracetam, brivaracetam, and valproic acid 1.
  • Other antiepileptic drugs such as topiramate, zonisamide, and benzodiazepines may be used 1.
  • Avoidance of triggering stimuli (e.g., flashing lights, loud noises) is recommended 1.
  • Special Populations

  • No information available in the provided abstracts.
  • Key Recommendations

  • Genetic testing for PIGL gene mutations is recommended for diagnosis 1. (Evidence: Strong)
  • Levetiracetam, brivaracetam, and valproic acid are recommended as first-line treatments for seizure control 1. (Evidence: Strong)
  • Patients should be advised to avoid triggering stimuli 1. (Evidence: Expert opinion)
  • References

    1 Zane Kellar J, Barrett H, Floyd J, Kim M, Barden M, An J et al.. What the . The western journal of emergency medicine 2024. link

    Original source

    1. [1]
      What the Zane Kellar J, Barrett H, Floyd J, Kim M, Barden M, An J et al. The western journal of emergency medicine (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG